Perrigo (PRGO) Cash from Investing Activities (2013 - 2026)

Perrigo's (PRGO) quarterly Cash from Investing Activities came in at -$12.4 million in Q1 2026, up 51.75% year-on-year from -$8.2 million in Q1 2025, and up 49.39% on a QoQ basis from -$24.5 million in Q4 2025.

Perrigo (PRGO) Cash from Investing Activities (2013 - 2026) Analysis & Trends

Perrigo (PRGO) has 14 years of Cash from Investing Activities data on file, last reported at -$12.4 million in Q1 2026.

  • On a quarterly basis, Cash from Investing Activities rose 51.75% year-over-year to -$12.4 million in Q1 2026; TTM through Mar 2026 was -$62.1 million, a 181.07% decrease from a year earlier, with the FY2025 full-year figure at -$75.4 million, down 195.69% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$12.4 million, up from -$24.5 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for PRGO reached as high as $212.7 million in Q3 2024 and fell as low as -$2.0 billion in Q3 2022.
  • Historically, Cash from Investing Activities has averaged -$120.3 million across 5 years, with a median of -$22.8 million in 2023.
  • Across the five-year window, Cash from Investing Activities tumbled 8956.88% in 2022 and jumped 792.83% in 2024, its largest moves.
  • Year by year, Cash from Investing Activities stood at -$26.0 million in 2022, then gained by 12.31% to -$22.8 million in 2023, then slumped by 62.72% to -$37.1 million in 2024, then surged by 33.96% to -$24.5 million in 2025, then soared by 49.39% to -$12.4 million in 2026.
  • Per Business Quant data, the three most recent Cash from Investing Activities figures were -$12.4 million in Q1 2026, -$24.5 million in Q4 2025, and -$21.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 89.42 Bn 87.55 Bn - -
2 Teva Pharmaceutical Industries 35.92 Bn 32.18 Bn 1.97 Bn 229.00 Mn
3 Zoetis 32.68 Bn 30.74 Bn 1.62 Bn -87.00 Mn
4 Takeda Pharmaceutical 27.63 Bn 23.57 Bn 4.39 Bn -369.95 Mn
5 United Therapeutics 23.16 Bn 21.01 Bn 648.10 Mn 743.70 Mn
6 RedHill Biopharma 21.80 Bn 21.80 Bn - -
7 Viatris 20.34 Bn 18.54 Bn 1.16 Bn 277.40 Mn
8 Neurocrine Biosciences 17.79 Bn 16.47 Bn 800.70 Mn -506.20 Mn
9 Elanco Animal Health 12.65 Bn 12.22 Bn 785.00 Mn -60.00 Mn
10 Perrigo 1.45 Bn 1.09 Bn 325.50 Mn -12.40 Mn

Historic Data

Download Data
DateValue
Mar 28, 2026 -12.40 Mn
Mar 28, 2026 -12.40 Mn
Dec 31, 2025 -24.50 Mn
Dec 31, 2025 -24.50 Mn
Sep 27, 2025 -21.40 Mn
Sep 27, 2025 -21.40 Mn
Jun 28, 2025 -3.80 Mn
Jun 28, 2025 -3.80 Mn
Mar 29, 2025 -25.70 Mn
Mar 29, 2025 -25.70 Mn
Dec 31, 2024 -37.10 Mn
Dec 31, 2024 -37.10 Mn
Sep 28, 2024 212.70 Mn
Sep 28, 2024 212.70 Mn
Jun 29, 2024 -73.30 Mn
Jun 29, 2024 -73.30 Mn
Mar 30, 2024 -23.50 Mn
Mar 30, 2024 -23.50 Mn
Dec 31, 2023 -22.80 Mn
Dec 31, 2023 -22.80 Mn